Pancreatic Cancer Research

ResearcherUniversity Hospitals Birmingham NHS Foundation TrustActive in the last 2 years

Robert Peter Sutcliffe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1881-7655; OpenAlex author ID A5080908798, A5121518341. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
86
Papers, trials and grants by year

2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: 3 papers · 2025: none · 2026: 7 papers

Papers 19

  1. Colonization of bile with gammaproteobacteria is associated with reduced survival after surgery for pancreatic cancer in patients receiving gemcitabine-based a… Co-author DOI 10.1016/j.ejso.2026.111396↗
  2. Effect of duration of neoadjuvant therapy on pancreatic cancer outcomes: a systematic review and meta-analysis. Co-author DOI 10.1016/j.hpb.2025.12.018↗
  3. Intention to treat outcomes following management of locally advanced pancreatic ductal adenocarcinoma with curative intent: single centre cohort study. Co-author DOI 10.1016/j.hpb.2026.06.008↗
  4. Temporary Mesocaval Shunt: A Surgical Strategy to Facilitate Pancreatic Cancer Resection With Complex Vascular Involvement. Co-author DOI 10.1111/ans.70977↗
  5. Neoadjuvant Chemoradiotherapy Versus Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis of Randomised Contro… Co-author DOI 10.1245/s10434-026-20319-7↗
  6. ASO Author Reflections: It is Time to Define an Optimal Duration of Neoadjuvant Treatment in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20436-3↗
  7. ASO Visual Abstract: Neoadjuvant Chemoradiotherapy versus Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis… Co-author DOI 10.1245/s10434-026-20533-3↗
  8. Can preoperative Carbohydrate Antigen 19-9 predict metastatic pancreatic cancer? Results of a systematic review and meta-analysis. Last author DOI 10.1016/j.hpb.2024.01.017↗
  9. Meta-analysis of survival after pulmonary resection for isolated metachronous pancreatic cancer metastasis: a promising, albeit infrequent, approach. Co-author DOI 10.1016/j.hpb.2024.05.015↗
  10. Staging Computed Tomography Parameters Predict the Need for Vein Resection during Pancreaticoduodenectomy in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/diagnostics14020135↗
  11. Are physical performance and frailty assessments useful in targeting and improving access to adjuvant therapy in patients undergoing resection for pancreatic c… Co-author DOI 10.1007/s00423-023-02828-1↗
  12. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  13. Vein Wall Invasion Is a More Reliable Predictor of Oncological Outcomes than Vein-Related Margins after Pancreaticoduodenectomy for Early Stages of Pancreatic … Co-author DOI 10.3390/diagnostics13223465↗
  14. Para-aortic lymph node involvement should not be a contraindication to resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.4240/wjgs.v14.i5.429↗
  15. Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience. Co-author DOI 10.1016/j.hpb.2021.03.003↗
  16. Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resect… Co-author DOI 10.1111/ans.16643↗
  17. Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study. Co-author DOI 10.1016/j.hpb.2020.01.005↗
  18. Laparoscopic versus open distal pancreatectomy for pancreatic adenocarcinoma: a systematic review and meta-analysis. Last author DOI 10.1080/00015458.2018.1492212↗
  19. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-gluco… Co-author DOI 10.3310/hta22070↗

Closest collaborators

The 25 strongest of 86 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keith John Roberts · 15 shared papers, 2018–2026 · strength 3.02
  2. David Christopher Bartlett · 12 shared papers, 2022–2026 · strength 2.90
  3. Nikolaos A. Chatzizacharias · 13 shared papers, 2020–2026 · strength 2.80
  4. S.S. Raza · 9 shared papers, 2024–2026 · strength 2.29
  5. Shahin Hajibandeh · 6 shared papers, 2024–2026 · strength 1.67
  6. Shahab Hajibandeh · 6 shared papers, 2024–2026 · strength 1.67
  7. Rupaly Pandé · 5 shared papers, 2020–2024 · strength 0.77
  8. Sarah F. Powell-Brett · 3 shared papers, 2023–2026 · strength 0.63
  9. Lewis A Hall · 2 shared papers, 2026 · strength 0.46
  10. Peter Lawrence Zaki Labib · 2 shared papers, 2026 · strength 0.46
  11. Moath Alarabiyat · 2 shared papers, 2026 · strength 0.46
  12. Adam Enver Frampton · 2 shared papers, 2021–2026 · strength 0.36
  13. Manish Singh Ahuja · 2 shared papers, 2022–2023 · strength 0.31
  14. Sivesh Kathir Kamarajah · 3 shared papers, 2021–2023 · strength 0.31
  15. Charlotte Terry · 1 shared paper, 2026 · strength 0.28
  16. Nabeel Merali · 1 shared paper, 2026 · strength 0.28
  17. Marit Kalisvaart · 2 shared papers, 2020–2021 · strength 0.21
  18. Francesca Marcon · 2 shared papers, 2020–2021 · strength 0.21
  19. Bilal A. Al-Sarireh · 2 shared papers, 2021–2023 · strength 0.19
  20. Shivan Sivakumar · 1 shared paper, 2026 · strength 0.18
  21. Mohammad Abu Hilal · 2 shared papers, 2018–2023 · strength 0.16
  22. Paschalis Gavriilidis · 1 shared paper, 2018 · strength 0.14
  23. Hemant Mahendrakumar Kocher · 2 shared papers, 2018–2021 · strength 0.13
  24. Yuk Ting Ma · 1 shared paper, 2021 · strength 0.11
  25. Pankaj Punia · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.